Gold prices continue to fall as HSBC casts doubts and predicts further decline
On Tuesday, October 6, during the Asian session, international spot gold continued to face downward pressure, at one point falling below the $4,110/oz level and hitting a low near $4,104, marking the second consecutive trading day of decline. With the Federal Reserve meeting minutes about to be released and both the US dollar and US Treasury yields remaining high, market sentiment is clearly bearish, making the defense of the $4,000 level once again the main focus of bulls and bears.
[News Brief]
US Treasury yields remain elevated, becoming the main obstacle to gold price increases. The 10-year US Treasury yield closed at about 5.31%, the highest since April 2002, while the 30-year yield rose to around 5.66%. Meanwhile, the US Dollar Index has strengthened and is on track to record its highest close since April 2025. This round of interplay between the forex and bond markets is putting pressure on non-interest-bearing gold in the short term.
However, market expectations for the Fed’s policy path have shifted significantly. Federal funds rate futures show the probability of a rate hike in October has dropped to around 22% to 24%, down from about 70% last week, although the risk of additional tightening in December hasn't been completely ruled out. The market's next focus will be the release of the September Fed meeting minutes at 2:00 pm (ET) on Wednesday, the weekly initial jobless claims at 8:30 am (UTC+8) on Thursday, and preliminary October consumer sentiment data at 10:00 am (UTC+8) on Friday. If labor market or sentiment data continue to weaken, this could further validate the cooling signal from the nonfarm payrolls report and so provide support for gold; if inflation expectations strengthen again, yields will likely continue to suppress gold prices.
After US personal consumption expenditures (PCE) inflation data turned out softer, traders’ bets on a Fed rate hike in October have cooled dramatically. The present market view is that there is only a 17% chance of a Fed rate hike in October, sharply down from 64% a week ago. Analysts point out that this change has dampened the previously hawkish expectations that suppressed gold, while also limiting further downside for gold prices.
At the same time, HSBC analysts have lowered their average gold price forecast for 2026 from $4,560 to $4,490, reflecting a more cautious outlook on gold’s further upside. However, the bank also emphasized that ongoing net purchases of gold by central banks worldwide remain an important pillar of support and are expected to continue limiting how deep gold price corrections may go.
[Latest International Gold Market Analysis]
Yesterday, gold once again showed a classic roller-coaster tug-of-war pattern. In early trading, international gold tested resistance at $4,163 before quickly falling back, reaching a low at $4,124; during the European session, there was a brief attempt to break above the $4,163 range, but bullish momentum remained insufficient and prices only touched $4,170 before slipping again. Late in the session, it dropped to near $4,123, and the daily chart closed with a doji, perfectly continuing the recent alternation between bullish and bearish candlesticks in this period of volatility.
From a historical technical perspective and routine patterns, today’s daily candlestick will probably close bearish. But, considering the US Dollar Index spiked and then retreated, this will provide some bottom-side support for gold, so intraday action is still likely to remain choppy within a range, rather than trending in a single direction.
Key support below: Pay particular attention to the overnight low around $4,123 — if price holds there, expect a narrow range and sideways action for the day.
If the price breaks this support effectively, gold could extend its decline to test the $4,100 level and then the critical support near $4,080. If it returns to the core support area, watch closely for signals of stabilization and recovery. Key resistance above: The early high of $4,145 is a short-term watershed between bulls and bears; if price tests this level and fails, watch for pullbacks. Once the market successfully holds above $4,145, it indicates that short-term bearish momentum is exhausted, limiting further downside for the day and putting the recent highs back in play. Strong resistance remains locked at the $4,200 level and the previous nonfarm payrolls high of $4,225.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ—US Stock Market Updates—MYR Group, Spyre Therapeutics, AMD
Search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Briefing": https://refini.tv/3dKUyB8 Reuters, October 6 - U.S. stock index futures rose on Tuesday as Treasury yields retreated from multi-year highs and oil prices declined, providing a bit of relief for investors ahead of the quarterly earnings season. ** MYR Group MYRG.O: Market Spotlight — Jefferies upgraded MYR Group to "Buy"; stock price rose nL4N45S0PK ** Spyre Therapeutics SYRE.O: Market Action — Spyre Therapeutics shares fell due to a $350 millions stock offering nL6N45S0PG ** AMD.O: Market Action — AMD shares rose on plans to increase chip supply nL4N45S0Q7 ** Constellation Energy CEG.O: Highlight — Alphabet reportedly close to signing a multi-year nuclear energy deal, Constellation Energy shares climbed nL6N45S0HX ** Nike NKE.N: Highlight — Berenberg downgraded Nike to "Sell"; shares declined nL6N45S0KB ** Option Care Health OPCH.O: Highlight — Option Care Health surged after reportedly receiving a buyout offer exceeding $5 billions nL4N45S0L5 ** Freshworks Inc FRSH.O: Market Action — Freshworks stock advanced as it is set to be added to the S&P SmallCap 600 nL4N45S0IT (For the convenience of non-English speakers, Reuters automatically translates its reports into various other languages. As automatic translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters is not responsible for any damage or loss caused by the use of automatic translation features.)
Top Premarket Decliners
07:38 AM EDT, 10/06/2026 (MT Newswires) -- Armada Acquisition Corp. II (XRPN) shares were down more than 16% in premarket activity Tuesday following a nearly 2% fall in the prior session. HeartSciences (HSCS) stock was 14% lower after a 1.4% gain in the prior session. WISeSat.Space (SAIQ) shares were down 13% after a 260% rise at the previous close. CTW (CTW) stock was 7% lower after remaining flat at Monday's close. Republic Power Group (RPGL) shares were down 4% after a regulatory filing showed that the company and its institutional investor mutually agreed to terminate an additional investment right, with Republic paying a $250,000 termination fee.

Oil prices fall below 100 yuan+Besent calls out, U.S. Treasury yields retreat from 2002 highs
U.S. Treasury yields have retreated from their highest levels since 2002.
BUZZ - Spyre Therapeutics shares tumble due to $350 million stock offering
On October 6, Spyre Therapeutics (SYRE.O) shares fell 4.1% to $88.90 in pre-market trading after the company priced a $350 million follow-on offering. The biotechnology firm announced late Monday that it was issuing approximately 4.1 million shares at $85 per share, an 8.3% discount to its last closing price. The company plans to use the net proceeds to advance its programs in gastroenterology, rheumatology, and dermatology, as well as to move a new project—SPY072—into later-stage development for the chronic skin disease hidradenitis suppurativa, among other uses. Jefferies, TD Cowen, Leerink, and Stifel are acting as joint book-running managers for the offering. On September 30, Merck’s (MRK.N) tulisokibart achieved success in a dermatology clinical trial, after which SYRE shares climbed about 5%. Analysts noted that the trial data supports SYRE's experimental candidate targeting the same signaling pathway. Headquartered in Waltham, Massachusetts, SYRE had around 88.2 million shares outstanding prior to the offering. As of Monday’s close, the stock had risen 183% year-to-date. According to LSEG data, 16 of 17 analysts rate the stock a “strong buy” or “buy,” with one analyst rating it “hold.” The median price target is $123. (For the convenience of non-English speakers, Reuters provides automated translations of its reports. Automated translations may contain errors or lack necessary context; Reuters makes no guarantee regarding the accuracy of machine translations and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation.)
